{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:43:41Z","timestamp":1793580221318,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020771","name":"Natural Science Foundation for Young Scientists of Shanxi Province","doi-asserted-by":"publisher","award":["2022JDTD0025"],"award-info":[{"award-number":["2022JDTD0025"]}],"id":[{"id":"10.13039\/501100020771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019936","name":"Key Laboratory of Heavy Rain and Drought-Flood Disasters in Plateau and Basins of Sichuan Province","doi-asserted-by":"publisher","award":["2021YB04"],"award-info":[{"award-number":["2021YB04"]}],"id":[{"id":"10.13039\/501100019936","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010012","name":"National Aerospace Science Foundation of China","doi-asserted-by":"publisher","award":["82073311"],"award-info":[{"award-number":["82073311"]}],"id":[{"id":"10.13039\/501100010012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejmech.2024.116781","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:20:40Z","timestamp":1723735240000},"page":"116781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Progress of ATM inhibitors: Opportunities and challenges"],"prefix":"10.1016","volume":"277","author":[{"given":"Shan","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-0282","authenticated-orcid":false,"given":"Jianyou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116781_bib1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1126\/science.7792600","article-title":"A single ataxia telangiectasia gene with a product similar to PI-3 kinase","volume":"268","author":"Savitsky K","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116781_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116781_bib3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/1744666X.2020.1810570","article-title":"Ataxia-telangiectasia: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management","volume":"16","author":"Amirifar","year":"2020","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.ejmech.2024.116781_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrfmmm.2020.111695","article-title":"Clinical potential of ATM inhibitors","volume":"821","author":"Lavin","year":"2020","journal-title":"Mutat. Res."},{"key":"10.1016\/j.ejmech.2024.116781_bib5","article-title":"Recent advances in synergistic antitumor effects exploited from the inhibition of ataxia telangiectasia and RAD3-related protein kinase (ATR)","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116781_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2024.116781_bib7","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116781_bib8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2024.116781_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2017.08.013","article-title":"DNA damage response inhibitors: mechanisms and potential applications in cancer therapy","volume":"60","author":"Carrassa","year":"2017","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2024.116781_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2015.12.009","article-title":"ATM kinase: much more than a DNA damage responsive protein","volume":"39","author":"Guleria","year":"2016","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2024.116781_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.07.002","article-title":"ATM in DNA repair in cancer","volume":"203","author":"Jin","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116781_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13046-019-1161-8","article-title":"Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK\/STAT3\/PD-L1 pathway","volume":"38","author":"Shen","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116781_bib13","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1038\/onc.2013.275","article-title":"ATM signalling and cancer","volume":"33","author":"Cremona","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116781_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116781_bib15","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-14-3502","article-title":"Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM","volume":"75","author":"McCabe","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116781_bib16","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1038\/s41388-022-02384-w","article-title":"A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers","volume":"41","author":"Oh","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116781_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40164-023-00416-z","article-title":"Genome-wide CRISPR\/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications","volume":"12","author":"Spalato-Ceruso","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2024.116781_bib18","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson I","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116781_bib19","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/jm061121y","volume":"50","author":"Hollick","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2014.08.003","article-title":"Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase","volume":"9","author":"Carruthers","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2024.116781_bib21","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.oraloncology.2012.05.020","article-title":"Autophagy and reactive oxygen species modulate cytotoxicity induced by suppression of ATM kinase activity in head and neck cancer cells","volume":"48","author":"Lin","year":"2012","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ejmech.2024.116781_bib22","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1158\/0008-5472.CAN-08-3883","article-title":"Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells","volume":"69","author":"Ivanov","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116781_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.canlet.2011.12.043","article-title":"Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling","volume":"319","author":"Fujimaki","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2024.116781_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1535-7163.MCT-08-1189","article-title":"The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt","volume":"9","author":"Li","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116781_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biocel.2017.03.015","article-title":"The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a \u03b3H2AX\/p-p53\/caspase-3-independent mechanism: inhibition of calpain and cathepsin D","volume":"87","author":"Chwastek","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116781_bib26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/cas.12899","article-title":"Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells","volume":"107","author":"Misumi","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2024.116781_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcimb.2019.00026","article-title":"Evaluation of ATM kinase inhibitor KU-55933 as potential anti-toxoplasma gondii agent","volume":"9","author":"Munera Lopez","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.ejmech.2024.116781_bib28","doi-asserted-by":"crossref","first-page":"20211","DOI":"10.1039\/C5NR05869D","article-title":"Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery","volume":"7","author":"Tian","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.ejmech.2024.116781_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/1535-7163.MCT-12-0707","article-title":"Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer","volume":"12","author":"Batey","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116781_bib30","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","article-title":"Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion","volume":"8","author":"Golding","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116781_bib31","series-title":"WO 2007\/026157","article-title":"Atm inhibitors","year":"2007"},{"key":"10.1016\/j.ejmech.2024.116781_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ijc.28680","article-title":"Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019","volume":"135","author":"Vecchio","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2024.116781_bib33","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/ijc.29121","article-title":"Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019","volume":"136","author":"Vecchio","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2024.116781_bib34","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190415","article-title":"EBV encoded miRNA BART8-3p promotes radioresistance in nasopharyngeal carcinoma by regulating ATM\/ATR signaling pathway","volume":"39","author":"Zhou","year":"2019","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejmech.2024.116781_bib35","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3892\/ol.2014.2444","article-title":"Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer","volume":"8","author":"Zhu","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2024.116781_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yexcr.2018.03.006","article-title":"ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin","volume":"366","author":"Li","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2024.116781_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13578-022-00778-7","article-title":"PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy","volume":"12","author":"Fischer","year":"2022","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ejmech.2024.116781_bib38","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.18632\/oncotarget.27723","article-title":"ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest","volume":"11","author":"Scotto","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116781_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010523","article-title":"Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease","volume":"6","author":"Lu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2024.116781_bib40","doi-asserted-by":"crossref","first-page":"15993","DOI":"10.1021\/acs.jmedchem.2c00799","article-title":"The emerging landscape of small-molecule therapeutics for the treatment of huntington's disease","volume":"65","author":"Ahamad","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2024.116781_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11910-021-01093-3","article-title":"Huntington's disease: new frontiers in therapeutics","volume":"21","author":"Pan","year":"2021","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.ejmech.2024.116781_bib43","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s12035-013-8591-7","article-title":"Mutations of the Huntington's disease protein impact on the ATM-dependent signaling and repair pathways of the radiation-induced DNA double-strand breaks: corrective effect of statins and bisphosphonates","volume":"49","author":"Ferlazzo","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2024.116781_bib44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1083\/jcb.200905138","article-title":"Mutant huntingtin impairs Ku70-mediated DNA repair","volume":"189","author":"Enokido","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.116781_bib45","first-page":"395","article-title":"Huntingtin is a scaffolding protein in the ATM oxidative DNA damage response complex","volume":"26","author":"Maiuri","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2024.116781_bib46","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/jnr.21881","article-title":"DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates","volume":"87","author":"Illuzzi","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejmech.2024.116781_bib47","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1021\/acs.jmedchem.8b01819","article-title":"Optimization of potent and selective ataxia telangiectasia-mutated inhibitors suitable for a proof-of-concept study in huntington's disease models","volume":"62","author":"Toledo-Sherman","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib48","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jmedchem.6b00519","article-title":"Discovery of novel 3-quinoline carboxamides as potent, selective, and orally bioavailable inhibitors of ataxia telangiectasia mutated (ATM) kinase","volume":"59","author":"Degorce","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib49","doi-asserted-by":"crossref","first-page":"110904","DOI":"10.18632\/oncotarget.22920","article-title":"The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy","volume":"8","author":"Greene","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116781_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920974201","article-title":"XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib","volume":"12","author":"Ali","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejmech.2024.116781_bib51","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","volume":"61","author":"Pike","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/B978-0-12-409547-2.13801-6","article-title":"Discovery of AZD0156: the first potent and selective inhibitor of ATM kinase for clinical evaluation","volume":"III","author":"Pike","year":"2017","journal-title":"Comprehensive Medicinal Chemistry"},{"key":"10.1016\/j.ejmech.2024.116781_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","article-title":"Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically","volume":"19","author":"Riches","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116781_bib54","series-title":"Tumor-specific Radiosensitizing Effect of the ATM Inhibitor AZD0156 in Melanoma Cells with Low Toxicity to Healthy Fibroblasts","author":"Scheper","year":"2022"},{"key":"10.1016\/j.ejmech.2024.116781_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007474","article-title":"ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models","volume":"11","author":"Jin","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejmech.2024.116781_bib56","first-page":"14","article-title":"DNA repair inhibitors potentiate fractionated radiotherapy more than single-dose radiotherapy in breast cancer cells","author":"Wong","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116781_bib57","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/psp4.13026","article-title":"Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway","volume":"12","author":"Hodson","year":"2023","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116781_bib58","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1158\/0008-5472.CAN-20-2960","article-title":"Inhibition of ATM induces hypersensitivity to proton irradiation by upregulating toxic end joining","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116781_bib59","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41416-018-0286-4","article-title":"pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry","volume":"119","author":"Jones","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2024.116781_bib60","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1186\/s12885-022-10084-7","article-title":"ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer","volume":"22","author":"Davis","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2024.116781_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd5750","article-title":"ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156","volume":"13","author":"Koneru","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2024.116781_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073834","article-title":"Targeting the DNA damage response to increase anthracycline-based chemotherapy cytotoxicity in T-cell lymphoma","volume":"23","author":"Magni","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116781_bib63","first-page":"149","volume":"vol. 52","author":"Jin","year":"2020"},{"key":"10.1016\/j.ejmech.2024.116781_bib64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/jm301297f","article-title":"Demystifying brain penetration in central nervous system drug discovery. Miniperspective","volume":"56","author":"Di","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib65","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.drudis.2019.01.015","article-title":"Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery","volume":"24","author":"Colclough","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2024.116781_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2024.116781_bib67","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1021\/acs.jmedchem.3c02277","article-title":"Identification of novel, selective ataxia-telangiectasia mutated kinase inhibitors with the ability to penetrate the blood-brain barrier: the discovery of AZD1390","volume":"67","author":"Pike","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj5962","article-title":"Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization","volume":"16","author":"Chen","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2024.116781_bib69","series-title":"Small Cell Lung Cancer Identified ATM Inhibitor (AZD1390) as a Radiosensitizer","article-title":"CRISPR screen of druggable targets","author":"Ran","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116781_bib70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1124\/jpet.122.001230","article-title":"Central nervous system distribution of the ataxia-telangiectasia mutated kinase inhibitor AZD1390: implications for the treatment of brain tumors","volume":"383","author":"Talele","year":"2022","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116781_bib71","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/neuonc\/noad064","article-title":"ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma","volume":"25","author":"Xie","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2024.116781_bib72","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1158\/1078-0432.CCR-23-0290","article-title":"ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis","volume":"29","author":"Tew","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116781_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.962","article-title":"The brain-penetrant ATM inhibitor, AZD1390, promotes axon regeneration and functional recovery in preclinical models of spinal cord injury","volume":"12","author":"Ahmed","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2024.116781_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109370","article-title":"AKT\/GSK3beta\/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosis","volume":"113","author":"Yang","year":"2022","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2024.116781_bib75","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/noaa238","article-title":"Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study","volume":"23","author":"Jucaite","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2024.116781_bib76","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1158\/1535-7163.MCT-17-0975","article-title":"Orally bioavailable and blood-brain barrier-penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice","volume":"17","author":"Karlin","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116781_bib77","article-title":"AZ32 reverses ABCG2-mediated multidrug resistance in colorectal cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116781_bib78","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1021\/acsmedchemlett.8b00200","article-title":"Discovery of a series of 3-cinnoline carboxamides as orally bioavailable, highly potent, and selective ATM inhibitors","volume":"9","author":"Barlaam","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116781_bib79","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-0763","article-title":"Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation","volume":"68","author":"Rainey","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116781_bib80","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/acs.jmedchem.5b01092","article-title":"Optimization of a novel series of ataxia-telangiectasia mutated kinase inhibitors as potential radiosensitizing agents","volume":"59","author":"Min","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib81","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1021\/acschembio.8b01020","article-title":"Chemoproteomic selectivity profiling of PIKK and PI3K kinase inhibitors","volume":"14","author":"Reinecke","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116781_bib82","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","article-title":"A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies","volume":"21","author":"Zimmermann","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116781_bib83","doi-asserted-by":"crossref","first-page":"492","DOI":"10.18632\/aging.204487","article-title":"Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death","volume":"15","author":"Chiu","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.ejmech.2024.116781_bib84","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.celrep.2020.01.052","article-title":"Cooperation of the ATM and Fanconi anemia\/BRCA pathways in double-strand break end resection","volume":"30","author":"Cai","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2024.116781_bib85","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10637-022-01216-8","article-title":"Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors","volume":"40","author":"Waqar","year":"2022","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2024.116781_bib86","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41594-021-00654-x","article-title":"Molecular basis of human ATM kinase inhibition","volume":"28","author":"Stakyte","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2024.116781_bib87","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.xphs.2021.10.011","article-title":"Atropisomerism - a neglected way to escape out of solubility flatlands","volume":"111","author":"Saal","year":"2022","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2024.116781_bib88","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1021\/acs.jmedchem.2c02104","article-title":"Design and optimization of novel benzimidazole- and imidazo[4,5-b]pyridine-based ATM kinase inhibitors with subnanomolar activities","volume":"66","author":"Dimitrov","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib89","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/acsmedchemlett.3c00034","article-title":"Discovery of [1,2,3]Triazolo[4,5-c]quinoline derivatives as a new class of ataxia-telangiectasia mutated kinase inhibitors","volume":"14","author":"Zhang","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116781_bib90","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1021\/acs.jmedchem.3c00082","article-title":"Discovery and evaluation of 3-quinoxalin urea derivatives as potent, selective, and orally available ATM inhibitors combined with chemotherapy for the treatment of cancer via goal-oriented molecule generation and virtual screening","volume":"66","author":"Deng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114196","article-title":"Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: computational simulation, biological evaluation and cancer combinational chemotherapy study","volume":"233","author":"Dou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib92","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1021\/ci500062f","article-title":"An unbiased method to build benchmarking sets for ligand-based virtual screening and its application to GPCRs","volume":"54","author":"Xia","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2024.116781_bib93","doi-asserted-by":"crossref","first-page":"73925","DOI":"10.18632\/oncotarget.18034","article-title":"Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity","volume":"8","author":"Dohmen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116781_bib94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116781_bib95","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial","volume":"100","author":"Fakhry","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2024.116781_bib96","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/erm.2020.4","article-title":"The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma","volume":"22","author":"Zhou","year":"2020","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116781_bib97","first-page":"12","article-title":"Targeting DNA double-strand break repair enhances radiosensitivity of HPV-positive and HPV-negative head and neck squamous cell carcinoma to photons and protons","author":"Vitti","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116781_bib98","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1017\/erm.2020.3","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116781_bib99","doi-asserted-by":"crossref","first-page":"38904","DOI":"10.1074\/jbc.M111.269134","article-title":"Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy","volume":"286","author":"Farkas","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116781_bib100","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1080\/15548627.2023.2182478","article-title":"Atg1-dependent phosphorylation of Vps34 is required for dynamic regulation of the phagophore assembly site and autophagy in Saccharomyces cerevisiae","volume":"19","author":"Lee","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2024.116781_bib101","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/nchembio.1681","article-title":"A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy","volume":"10","author":"Ronan","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116781_bib102","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1021\/acs.jmedchem.1c00114","article-title":"Structure-based exploration of selectivity for ATM inhibitors in huntington's disease","volume":"64","author":"Van de Po\u00ebl","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424006627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424006627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T12:15:12Z","timestamp":1738412112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424006627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":102,"alternative-id":["S0223523424006627"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116781","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress of ATM inhibitors: Opportunities and challenges","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116781"}}